X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12558) 12558
Newspaper Article (88) 88
Magazine Article (38) 38
Book / eBook (27) 27
Newsletter (15) 15
Conference Proceeding (8) 8
Book Chapter (6) 6
Dissertation (5) 5
Reference (4) 4
Journal / eJournal (3) 3
Publication (2) 2
Web Resource (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9872) 9872
antibiotics, antineoplastic - therapeutic use (6144) 6144
female (5641) 5641
male (4716) 4716
animals (4282) 4282
middle aged (3324) 3324
antibiotics, antineoplastic - administration & dosage (3273) 3273
oncology (3230) 3230
adult (2946) 2946
aged (2661) 2661
cancer (2563) 2563
mice (2456) 2456
chemotherapy (2411) 2411
antibiotics, antineoplastic - pharmacology (2113) 2113
doxorubicin (2028) 2028
antibiotics, antineoplastic - adverse effects (1921) 1921
pharmacology & pharmacy (1866) 1866
doxorubicin - therapeutic use (1741) 1741
doxorubicin - administration & dosage (1709) 1709
treatment outcome (1697) 1697
antineoplastic combined chemotherapy protocols - therapeutic use (1627) 1627
cell line, tumor (1458) 1458
anthracyclines (1388) 1388
antibiotics (1240) 1240
breast neoplasms - drug therapy (1165) 1165
neoplasms - drug therapy (1160) 1160
antineoplastic agents - therapeutic use (1102) 1102
apoptosis (1029) 1029
therapy (1017) 1017
rats (996) 996
doxorubicin - pharmacology (977) 977
adolescent (915) 915
tumors (873) 873
care and treatment (800) 800
analysis (785) 785
combined modality therapy (779) 779
antibiotics, antineoplastic - pharmacokinetics (778) 778
dose-response relationship, drug (771) 771
doxorubicin - adverse effects (747) 747
time factors (746) 746
research (742) 742
antibiotics, antineoplastic - toxicity (736) 736
child (720) 720
apoptosis - drug effects (702) 702
breast cancer (702) 702
drugs (699) 699
aged, 80 and over (693) 693
expression (686) 686
medicine & public health (680) 680
retrospective studies (680) 680
health aspects (670) 670
drug delivery systems (660) 660
mitomycin - therapeutic use (631) 631
follow-up studies (627) 627
mice, nude (626) 626
antibiotics, antineoplastic - chemistry (623) 623
surgery (609) 609
mice, inbred balb c (603) 603
toxicity (603) 603
cell survival - drug effects (586) 586
drug therapy (582) 582
prognosis (571) 571
hematology (569) 569
breast neoplasms - pathology (568) 568
prospective studies (556) 556
cardiotoxicity (552) 552
tumor cells, cultured (546) 546
drug resistance, neoplasm (536) 536
cells (534) 534
doxorubicin - pharmacokinetics (529) 529
risk factors (524) 524
proteins (518) 518
drug resistance (508) 508
antineoplastic combined chemotherapy protocols - adverse effects (505) 505
nanoparticles (498) 498
cancer therapies (490) 490
carcinoma (487) 487
biochemistry & molecular biology (486) 486
medicine (486) 486
adriamycin (480) 480
cell proliferation - drug effects (473) 473
doxorubicin - analogs & derivatives (471) 471
bleomycin - therapeutic use (470) 470
in-vitro (462) 462
disease-free survival (455) 455
drug administration schedule (454) 454
antineoplastic agents - pharmacology (453) 453
chemistry, multidisciplinary (450) 450
child, preschool (450) 450
survival analysis (450) 450
liposomes (449) 449
lung neoplasms - drug therapy (448) 448
cytotoxicity (446) 446
survival rate (445) 445
doxorubicin - toxicity (431) 431
antineoplastic agents - administration & dosage (430) 430
disease models, animal (429) 429
drug therapy, combination (429) 429
antineoplastic agents - adverse effects (414) 414
research article (413) 413
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (16) 16
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Gerstein Science - Periodical Stacks (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Gerstein Science - Bindery (2) 2
Online Resources - Online (2) 2
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11654) 11654
Japanese (444) 444
Russian (283) 283
French (245) 245
German (189) 189
Chinese (115) 115
Italian (68) 68
Spanish (48) 48
Polish (28) 28
Portuguese (24) 24
Dutch (17) 17
Hungarian (17) 17
Czech (14) 14
Danish (11) 11
Ukrainian (11) 11
Norwegian (9) 9
Finnish (7) 7
Serbian (7) 7
Romanian (4) 4
Turkish (4) 4
Lithuanian (3) 3
Croatian (2) 2
Korean (2) 2
Swedish (2) 2
Bulgarian (1) 1
Hebrew (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 1528-0020, 2014, Volume 123, Issue 21, pp. 3239 - 3246
Journal Article
Annals of oncology, ISSN 0923-7534, 2012, Volume 23, Issue 12, pp. 3069 - 3074
Luminal breast cancer is a highly endocrine responsive disease. However, the therapeutic benefit of chemotherapy (CT... 
luminal breast cancer | neoadjuvant | hormonotherapy | chemotherapy | Neoadjuvant | Chemotherapy | Hormonotherapy | Luminal breast cancer | SURVIVAL | SUBTYPES | GENE-EXPRESSION PROFILES | PATHOLOGICAL RESPONSE | MARKERS | ENDOCRINE THERAPY | TRIAL | PREOPERATIVE CHEMOTHERAPY | MOLECULAR PORTRAITS | ONCOLOGY | PROGNOSTIC-SIGNIFICANCE | Receptors, Estrogen - metabolism | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Antineoplastic Agents - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Receptors, Progesterone - metabolism | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Taxoids - adverse effects | ErbB Receptors - metabolism | Docetaxel | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Keratin-8 - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Keratin-18 - metabolism | Neoadjuvant Therapy - adverse effects | Epirubicin - therapeutic use | Aged | Antineoplastic Agents, Alkylating - adverse effects | Epirubicin - adverse effects | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2014, Volume 111, Issue 38, pp. 13817 - 13821
The recent success of antibody-drug conjugates (ADCs) in the treatment of cancer has led to a revived interest in microtubuledestabilizing agents. Here, we... 
Microtubules | Drug interactions | Antineoplastics | Ligands | Dimers | Breast cancer | Molecular mechanisms of action | Crystallography | Binding sites | Crystal structure | X-ray crystallography | Microtubule-targeting agents | Drug mechanism | microtubule-targeting agents | BETA-TUBULIN | VINCA-DOMAIN | MAYTANSINE | MULTIDISCIPLINARY SCIENCES | RESOLUTION | ANTIMITOTIC AGENTS | MACROCYCLIC LACTONE ANTIBIOTICS | POTENT ANTITUMOR-ACTIVITY | BREAST-CANCER | STRUCTURAL BASIS | RHIZOXIN | drug mechanism | Tubulin Modulators - chemistry | Humans | Polyketides - chemistry | Antineoplastic Agents, Phytogenic - chemistry | Crystallography, X-Ray | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Tubulin Modulators - therapeutic use | Pyrones - chemistry | Animals | Antibiotics, Antineoplastic - chemistry | Antibiotics, Antineoplastic - therapeutic use | Macrolides - chemistry | Cattle | Maytansine - chemistry | Pyrones - therapeutic use | Female | Microtubules - chemistry | Tubulin - chemistry | Antineoplastic Agents, Phytogenic - therapeutic use | Macrolides - therapeutic use | Polyketides - therapeutic use | Binding Sites | Clinical Trials, Phase I as Topic | Antimitotic agents | Pharmaceutical research | Physiological aspects | Dosage and administration | Research | Tubulins | Antineoplastic agents | Binding sites (Biochemistry) | Biological Sciences
Journal Article
Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 4, pp. 397 - 407
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2012, Volume 8, Issue 1, pp. 81 - 92
Abstract The present study demonstrates the applicability of a novel strategy that employs targeted delivery of combined treatment against tumor... 
Internal Medicine | Tumor neovasculature | Combretastatin A4 | Combination therapy | Targeted delivery | Doxorubicin | MEDICINE, RESEARCH & EXPERIMENTAL | DIBLOCK COPOLYMERS | CELLS | GENE DELIVERY | DRUG-DELIVERY | NANOSCIENCE & NANOTECHNOLOGY | MULTIFUNCTIONAL POLYMERIC MICELLES | METRONOMIC CHEMOTHERAPY | PACLITAXEL | RGD PEPTIDE | ANGIOGENESIS INHIBITORS | INTRACELLULAR DELIVERY | Human Umbilical Vein Endothelial Cells | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Stilbenes - administration & dosage | Stilbenes - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - chemistry | Humans | Polyethylene Glycols - chemistry | Doxorubicin - chemistry | Stilbenes - chemistry | Polyethylene Glycols - therapeutic use | Drug Carriers - chemistry | Peptides, Cyclic - chemistry | Drug Delivery Systems | Antineoplastic Agents, Phytogenic - administration & dosage | Antibiotics, Antineoplastic - chemistry | Melanoma, Experimental | Micelles | Antineoplastic Agents, Phytogenic - therapeutic use | Lactates - chemistry | Doxorubicin - administration & dosage | Mice, Inbred C57BL | Antineoplastic Agents, Phytogenic - chemistry | Lactates - therapeutic use | Antibiotics, Antineoplastic - administration & dosage | Animals | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Peptides, Cyclic - therapeutic use | Cell Proliferation - drug effects | Mice | Anthracyclines | Dosage and administration | Tumors | Integrins
Journal Article
Journal of controlled release, ISSN 0168-3659, 2016, Volume 229, pp. 154 - 162
PEGylated liposomes have transformed chemotherapeutic use of doxorubicin by reducing its cardiotoxicity... 
Synergistic | Nanoparticles | Chemotherapy | Drug combinations | Liposomes | CATIONIC LIPOSOMES | TUMOR-CELLS | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | BREAST-CANCER | 5-FLUOROURACIL | CIRCULATION TIME | RANDOMIZED PHASE-III | ADVANCED GASTRIC-CANCER | PHARMACOLOGY & PHARMACY | EUROPEAN-ORGANIZATION | THERAPEUTIC ACTIVITY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antimetabolites, Antineoplastic - pharmacokinetics | Humans | Tryptophan - chemistry | Polyethylene Glycols - chemistry | Doxorubicin - chemistry | Antimetabolites, Antineoplastic - administration & dosage | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Antibiotics, Antineoplastic - chemistry | Female | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - administration & dosage | Cell Line | Antimetabolites, Antineoplastic - chemistry | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Animals | Antibiotics, Antineoplastic - therapeutic use | Tumor Burden - drug effects | Fluorouracil - chemistry | Cell Line, Tumor | Mice, Inbred BALB C | Fluorouracil - pharmacokinetics | Neoplasms - pathology | Drug Combinations | Drugs | Anthracyclines | Drug delivery systems | Sulfates | Vehicles | Cancer | School facilities | Biomedical engineering | Education parks | Index Medicus | synergistic | nanoparticles | liposomes | chemotherapy
Journal Article
American journal of hematology, ISSN 0361-8609, 2013, Volume 88, Issue 11, pp. 961 - 966
Clofarabine is a second generation nucleoside analogue with activity in adults with acute myeloid leukemia (AML). A phase I trial of clofarabine, idarubicin,... 
PHASE-III TRIAL | SOUTHWEST-ONCOLOGY-GROUP | DOSE CYTOSINE-ARABINOSIDE | GROUP-B | ARA-C | DAUNORUBICIN | HEMATOLOGY | CANCER | CHEMOTHERAPY | MODULATION | INDUCTION TREATMENT | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Follow-Up Studies | Nausea - chemically induced | Cytarabine - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Antimetabolites, Antineoplastic - administration & dosage | Young Adult | Arabinonucleosides - administration & dosage | Idarubicin - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Idarubicin - administration & dosage | Adenine Nucleotides - administration & dosage | Idarubicin - therapeutic use | Drug Eruptions - etiology | Adenine Nucleotides - therapeutic use | Arabinonucleosides - adverse effects | Remission Induction | Arabinonucleosides - therapeutic use | Cytarabine - administration & dosage | Adenine Nucleotides - adverse effects | Induction Chemotherapy - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Pilot Projects | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Consolidation Chemotherapy - adverse effects | Anthracyclines | Index Medicus | AML | idarubicin | cytarabine | frontline therapy | clofarabine
Journal Article
Annals of oncology, ISSN 0923-7534, 03/2014, Volume 25, Issue 3, pp. 592 - 598
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2005, Volume 23, Issue 34, pp. 8597 - 8605
Journal Article
Annals of oncology, ISSN 0923-7534, 2014, Volume 25, Issue 3, pp. 599 - 605
Journal Article